source
- Summit Therapeutics cancels $500 million secondary share offering citing market conditionsSummit Therapeutics announced it would pull a planned $500 million secondary share sale just one day after the announcement, saying market conditions were unfavorable. The offering had been slated…
- DHL in talks with major pharma firms to manage sites amid ongoing trade disruptionsDHL's healthcare logistics division is currently in discussions with several leading pharmaceutical manufacturers. The drugmakers are exploring options for DHL to either assume control of their ma…